Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

The stock has dropped 56% over the last 12 months. Analysts led by Salveen Richter lowered Moderna's rating to neutral from buy as they say Moderna has limited visibility on the revenue stream for ...

While the revised outlook appears feasible, it "leads us to believe MRNA has limited visibility on the revenue stream for the respiratory vaccine business," analyst Salveen Richter wrote ...

Apellis Pharmaceuticals (APLS – Research Report) received a Hold rating and price target from Goldman Sachs analyst Salveen Richter today. The company’s shares closed yesterday at $33.66.

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. The latest guidance reduction was the second time in the last six months that the ...